Distribution of human hematopoietic cells in iBM or intravenously injected NOD/SCID mice
| Mouse . | Percentage of human CD45+cells . | Lymphoid . | Myeloid . | Stem/progenitor . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Right . | Left . | Spl . | PB . | Right . | Left . | Right . | Left . | Right . | Left . | |
| iBM | ||||||||||
| 1 | 44.21 | 0.60 | 2.46 | ND | 67.13 | 63.26 | 6.96 | 18.68 | 28.94 | 13.98 |
| 2 | 15.83 | 12.00 | 0.85 | ND | 82.82 | 82.79 | 3.64 | 9.54 | 19.62 | 6.09 |
| 3 | 34.85 | 77.90 | 34.65 | ND | 69.43 | 59.60 | 4.39 | 5.57 | 20.66 | 29.92 |
| 4 | 55.73 | 50.43 | 31.92 | ND | 62.21 | 68.69 | 7.22 | 8.96 | 19.86 | 22.83 |
| 5 | 17.57 | 4.76 | 2.42 | ND | 69.35 | 70.87 | 8.62 | 16.00 | 26.59 | 22.68 |
| 6 | 77.81 | 84.74 | 41.83 | 14.48 | 65.16 | 84.50 | 31.78 | 8.53 | 13.29 | 22.75 |
| 7 | 96.07 | 34.23 | 34.15 | 11.67 | 67.21 | 63.01 | 14.64 | 13.89 | 24.83 | 21.56 |
| 8 | 28.40 | 1.84 | 4.33 | 0.97 | 57.12 | 62.66 | 12.41 | 10.76 | 12.84 | 10.89 |
| 9 | 39.11 | 1.87 | 4.04 | 2.05 | 70.45 | 68.73 | 4.71 | 5.96 | 22.37 | 28.04 |
| Mean (± SD) | 45.51 (26.96) | 29.82 (33.79) | 17.41 (17.52) | 7.29 (6.79) | 67.88 (6.99) | 69.35 (8.88) | 10.49 (8.79) | 10.88 (4.47) | 21.00 (5.48) | 19.86 (7.91) |
| Intravenous | ||||||||||
| 1 | 49.10 | 52.46 | 39.18 | 8.19 | 74.02 | 75.04 | 14.40 | 11.50 | 12.71 | 19.36 |
| 2 | 32.29 | 21.77 | 3.64 | 1.97 | 86.51 | 85.86 | 4.08 | 5.07 | 6.00 | 9.03 |
| 3 | 42.37 | 39.48 | 18.35 | 5.52 | 69.54 | 71.22 | 6.99 | 9.32 | 11.59 | 14.02 |
| 4 | 22.69 | 16.63 | 9.20 | 2.01 | 86.32 | 73.07 | 10.38 | 12.67 | 19.31 | 21.79 |
| 5 | 28.16 | 22.76 | 21.16 | 4.85 | 80.36 | 79.76 | 13.65 | 15.07 | 16.88 | 14.22 |
| 6 | 19.67 | 22.54 | 7.55 | 1.36 | 68.41 | 65.59 | 7.98 | 11.65 | 19.28 | 16.71 |
| 7 | 12.90 | 8.92 | 6.50 | 1.74 | 62.05 | 95.64 | 30.65 | 3.18 | 11.18 | 9.29 |
| Mean (± SD) | 29.6 (12.77) | 26.37 (14.72) | 15.08 (12.41) | 3.66 (2.58) | 75.32 (9.40) | 78.03 (10.08) | 12.59 (8.76) | 9.78 (4.26) | 13.85 (4.89) | 14.92 (4.79) |
| Mouse . | Percentage of human CD45+cells . | Lymphoid . | Myeloid . | Stem/progenitor . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Right . | Left . | Spl . | PB . | Right . | Left . | Right . | Left . | Right . | Left . | |
| iBM | ||||||||||
| 1 | 44.21 | 0.60 | 2.46 | ND | 67.13 | 63.26 | 6.96 | 18.68 | 28.94 | 13.98 |
| 2 | 15.83 | 12.00 | 0.85 | ND | 82.82 | 82.79 | 3.64 | 9.54 | 19.62 | 6.09 |
| 3 | 34.85 | 77.90 | 34.65 | ND | 69.43 | 59.60 | 4.39 | 5.57 | 20.66 | 29.92 |
| 4 | 55.73 | 50.43 | 31.92 | ND | 62.21 | 68.69 | 7.22 | 8.96 | 19.86 | 22.83 |
| 5 | 17.57 | 4.76 | 2.42 | ND | 69.35 | 70.87 | 8.62 | 16.00 | 26.59 | 22.68 |
| 6 | 77.81 | 84.74 | 41.83 | 14.48 | 65.16 | 84.50 | 31.78 | 8.53 | 13.29 | 22.75 |
| 7 | 96.07 | 34.23 | 34.15 | 11.67 | 67.21 | 63.01 | 14.64 | 13.89 | 24.83 | 21.56 |
| 8 | 28.40 | 1.84 | 4.33 | 0.97 | 57.12 | 62.66 | 12.41 | 10.76 | 12.84 | 10.89 |
| 9 | 39.11 | 1.87 | 4.04 | 2.05 | 70.45 | 68.73 | 4.71 | 5.96 | 22.37 | 28.04 |
| Mean (± SD) | 45.51 (26.96) | 29.82 (33.79) | 17.41 (17.52) | 7.29 (6.79) | 67.88 (6.99) | 69.35 (8.88) | 10.49 (8.79) | 10.88 (4.47) | 21.00 (5.48) | 19.86 (7.91) |
| Intravenous | ||||||||||
| 1 | 49.10 | 52.46 | 39.18 | 8.19 | 74.02 | 75.04 | 14.40 | 11.50 | 12.71 | 19.36 |
| 2 | 32.29 | 21.77 | 3.64 | 1.97 | 86.51 | 85.86 | 4.08 | 5.07 | 6.00 | 9.03 |
| 3 | 42.37 | 39.48 | 18.35 | 5.52 | 69.54 | 71.22 | 6.99 | 9.32 | 11.59 | 14.02 |
| 4 | 22.69 | 16.63 | 9.20 | 2.01 | 86.32 | 73.07 | 10.38 | 12.67 | 19.31 | 21.79 |
| 5 | 28.16 | 22.76 | 21.16 | 4.85 | 80.36 | 79.76 | 13.65 | 15.07 | 16.88 | 14.22 |
| 6 | 19.67 | 22.54 | 7.55 | 1.36 | 68.41 | 65.59 | 7.98 | 11.65 | 19.28 | 16.71 |
| 7 | 12.90 | 8.92 | 6.50 | 1.74 | 62.05 | 95.64 | 30.65 | 3.18 | 11.18 | 9.29 |
| Mean (± SD) | 29.6 (12.77) | 26.37 (14.72) | 15.08 (12.41) | 3.66 (2.58) | 75.32 (9.40) | 78.03 (10.08) | 12.59 (8.76) | 9.78 (4.26) | 13.85 (4.89) | 14.92 (4.79) |
BM cells, spleen cells, and PB of NOD/SCID mice 6 to 9 weeks after iBM or intravenous transplantation of column-enriched but unsorted whole CD34+ cell populations (20 000 cell for iBM and 200 000 cells for intravenous) were stained with antihuman CD45 mAbs and analyzed. BM cells were collected separately from injected (right leg) and noninjected (left leg) side tibia. Lymphoid, myeloid, and stem/progenitor cell lineages are defined as CD19+/CD45+ cells, CD33+/CD45+ cells, and CD34+/CD45+ cells, respectively, and each number indicates the percentage of human CD45+ cells expressing respective surface marker. The proportion of each lineage was calculated from 50 000 to 100 000 events acquired using CELLQuest software.
ND indicates not determined.